Jocasta Neuroscience, a preclinical stage, longevity-focused company, with its lead asset, a proprietary formulation of the longevity protein, a - Klotho, for the treatment of conditions, including cognitive impairment in neurodegenerative diseases, today announced it has raised $35 million in a Series A financing.

The round was led by early-stage venture capital firm True Ventures and joined by Moore Strategic Ventures, SC8 Investments, Glentura, Yagan Family Foundation, and others. Kevin Rose of True Ventures will join Dr. Michael Davidson, COB, and Dr. Albert Agro (CEO) on the Jocasta Board of Directors.

Jocasta Neuroscience is a pre-clinical stage biotech company focused on developing a proprietary formulation of a-Klotho protein (JN-0413) to manage cognitive decline associated with various forms of neurodegenerative-induced dementia. Jocasta's foundational data demonstrates the critical role of a-Klotho in health and disease. Results ranging from human genetics (effect of KL mutations in humans) to robust cognitive enhancement in healthy rats, rodent disease models and non-human primates strongly support the advancement of JN-0413 into clinical trials in patients with dementia and cognitive decline.